Experimental study on closing bicirculating bioartificial liver support system for treatment of acute hepatic failure in canines

YU De-cai,QIU Yu-dong,XU Qing-xiang,DING Yi-tao

DOI: https://doi.org/10.3760/cma.j.issn.1673-9752.2006.04.010

2006-01-01

Abstract:Objective To study and evaluate the stability, safety and efficacy of closing bicirculating bioartificial liver support system (CBC-BALSS) in treatment of acute hepatic failure in canines. Methods Twenty canine models with acute hepatic failure were set up through end-side portocaval shunt with common bile duct transaction and then treated with CBC-BALSS (treatment group, n =11) or no hepatocyte CBC-BALSS (control group, n =9) for six hours. Serum ammonia, biochemical functions, factor Ⅶ, BCAA/AAA and monoethylglycinexylidide (MEGX) in serum of subjects and density, viability and number of hepatocytes in cell circulation were detected in treatment group. Results The total volume of hepatocyte solution was 200 ml, with number, density and viability of hepatocyte for 1×10 10 , 5×107/ml and 98% respectively. During operation, stable clinical vital signs but transient hypotension within 30 minutes were seen in 16 canines including two with allergic reaction after 15 minutes (one per group), one death due to upper gastrointestinal hemorrhage and one death because of hemorrhage at puncture spot in CBC-BALSS group. Before treatment, serum ammonia, ALT, total/direct bilirubin, factor Ⅶ and BCAA/AAA were 150 mmol/L, 400 U/L, 80/55 mmol/L, 35 g/L, 20% and 1.6, respectively. After treatment for six hours, serum ammonia and total/direct bilirubin decreased more significantly in treatment group than those in control group. ALT decreased significantly and showed statistical difference at the sixth hour. But there was no statistical difference in factor Ⅶ, BCAA/AAA and ALP between two groups at all time points. There was statistical difference in MEGX at the first and second hours, with climax of treatment group arrived earlier two hours. Bicirculating pressure was elevated to 115 mm Hg gradually, fluctuating at ±5 mm Hg. ALT increased significantly in treatment group. No statistical difference was found two groups upon Tbil/Dbil that increased at all time points. Changes of ALT had no statistical difference.Conclusion ICBC-BALSS is efficacious, safe and stable for treating acute hepatic failure in canines and exerts marked metabolic function.